Summarized by Masters of Longevity from PR Newswire.
Sac-TMT plus pembrolizumab delayed progression in selected advanced lung cancer patients. Overall survival remains preliminary.

Key Takeaways
- The trial enrolled PD-L1-negative patients without EGFR or ALK mutations.
- Median progression-free survival was 15.0 months versus 5.7 months.
- An overall survival benefit has not yet been established.



